Abstract
Objective: To investigate the effect of administration of the catechol-O-methyltransferase (COMT) inhibitor tolcapone on the concentration-effect relationship of levodopa in patients with advanced Parkinson’s disease and on-off fluctuations.
Design: Nonblind single-group 2-period pharmacokinetic-pharmacodynamic study.
Patients and participants: 12 patients, mean age 59 years, with idiopathic Parkinson’s disease and response fluctuations.
Methods: The pharmacokinetics [plasma concentrations of levodopa and 3-O-methyldopa (3-OMD)] and motor effects [global score of the Columbia University Rating Scale (CURS∑)] of levodopa (plus the peripheral decarboxylase inhibitor benserazide 1: 4) were determined for 4 consecutive dosage intervals (4 hours each, starting at 8.00am) in 12 patients before (day 1) and during (day 8) coadministration of tolcapone 100mg 3 times daily for 7 days.
Results: Under tolcapone, exposure to levodopa [area under the plasma concentration-time for the dosage interval (AUCτ)] observed for the separate doses increased by 1.6- to 2.2-fold, and peak plasma drug concentrations (Cmax) increased by 1.1- to 2.1-fold. 3-OMD concentrations at day 8 were reduced to about 20% of the values at day 1. At baseline (day 1, before the first levodopa dose), CURS∑ averaged 40 ± 10 points. After the first levodopa dose, CURS∑ declined to 20 ± 9 points. At day 8, the predose CURS∑ decreased to a final score of 31 ±13 points, and the maximal decline after the first levodopa dose was to a final score of 16 ± 8 points. Population analysis (NONMEM) of the concentration-effect relationship of levodopa according to a sigmoidal Emax model and over all dosage intervals did not show differences in levodopa responsiveness with or without tolcapone. The population mean of the 50% effective concentration (EC50) of levodopa was 1350 μg/L with an standard error of the population parameter estimate of 18%; adding tolcapone treatment as a covariate did not significantly change the population fit. Circadian influences on levodopa responsiveness were not evaluable by the NONMEM model due to overparametrisation, but visual inspection of plotted data did not suggest differences in the concentration-effect relationship between the 4 consecutive dosage intervals on days 1 and 8.
Conclusions: The gain in clinical improvement with levodopa under tolcapone can be fully explained by tolcapone-induced changes of peripheral levodopa pharmacokinetics. We suggest that this interaction study, performed in patients and using clinical data, excludes any central effects of tolcapone or any inhibiting effect of 3-OMD on levodopa permeation through the blood-brain barrier, which otherwise would have led to a decrease in the EC50 of levodopa.
Similar content being viewed by others
References
Sage JI, Mark MH. Basic mechanisms of motor fluctuations. Neurology 1994; 44 Suppl. 6: S10–4
Hagan JJ, Middlemiss DN, Sharpe PC, et al. Parkinson’s disease: prospects for improved drug therapy. Trends Pharmacol Sci 1997; 18: 157–64
Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord 1999; 14: 911–3
Cedarbaum JM. Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet 1987; 13: 141–78
Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson’s disease. Neurology 1998; 50 Suppl. 6: S11–4
Contin M, Riva R, Albani F, et al. Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin Pharmacokinet 1996; 30: 463–81
Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988; 38: 533–6
Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson’s disease. Ann Neurol 1991; 29: 556–9
Li Y, Wirth T, Huotari M, et al. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Eur J Clin Pharmacol 1998; 356: 127–37
Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson’s disease. J Neurol 1998; 245 Suppl. 3: P25–34
Zürcher G, Colzi A, DaPrada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm 1990; 32 Suppl.: 375–80
Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs 2000; 59(6): 1233–50
Jorga K, Fotteler B, Schmitt M, et al. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 1997; 38: 59–67
Sedek G, Jorga KM, Burns R, et al. Effect of tolcapone on plasma levodopa levels after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997; 10: 531–41
Jorga KM, Sedek G, Fotteler B, et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997; 62: 300–10
Rajput AH, Martin W, Saint-Hiliaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the ‘wearing-off’ phenomenon: a double blind, placebo-controled, multicenter trial. Neurology 1997; 49: 1066–71
Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long term treatment. Neurology 1997; 49: 665–71
Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983; 33: 278–82
Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 1987; 21(6): 584–8
Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with PD. Clin Pharmacokinet 1995; 26: 243–56
Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic PD: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–4
Hoehn MM, Yahr MD. Parkinsonism: onset progression and mortality. Neurology 1967; 4: 427–42
Barruzi A, Contin M, Albani F, et al. Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by HPLC with coulorimetric detection. J Chromatogr 1986; 375: 165–9
Montgomery GK, Reynolds NC, Warren RM. Qualitative assessment of Parkinson’s disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 1985; 8: 83–92
Baas H, Stecker K, Fischer PA. Value and appropriate use of rating scales and apparative measurements in quantification of disability in PD. J Neurol Transm 1993; 5: 45–61
Unadkat JD, Bartha F, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86–93
Jorga K, Banken L, Fotteler B, et al. Population pharmacokinetics of levodopa in patients with Parkinson’s disease treated with tolcapone. Clin Pharmacol Ther 2000; 67: 610–20
Harder S, Baas H, Bergemann N, et al. Concentration/effect relationship of levodopa in patients with Parkinson’s disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 1995; 39: 39–44
Baas H, Harder S, Bürcklin F, et al. Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations. Clin Neuropharmacol 1998; 21: 86–92
Harder S, Baas H. Concentration-response relationship of levodopa in patients at different stages of PD. Clin Pharmacol Ther 1998; 64: 183–91
Contin M, Riva R, Martinelli P, et al. A levodopa kinetic-dynamic study of the rate of progression in Parkinsons Disease. Neurology 1998; 51: 1075–80
Contin M, Riva R, Martinelli P, et al. Pharmacodynamic modeling of oral levodopa. Neurology 1993; 43: 367–71
Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996; 51: 59–67
Benetello P, Furlanut M, Fortunate M, et al. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res 1997; 35: 313–5
Guttman M, Leger G, Cedarbaum JM, et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992; 31: 638–43
Doudet DJ, Chan GL, Holden JE, et al. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 1997; 36: 363–71
Huotari M, Gainetdinov R, Männistö PT. Microdialysis studies on the action of tolcapone on pharmacologically elevated extracellular dopamine levels in conscious rat. Pharmacol Toxicol 1999; 85: 233–8
Hauder RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson’s disease patients. Mov Disord 1998; 13: 643–7
Acknowledgements
This study has been sponsored by a grant from Roche Pharmaceuticals, Basel, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baas, H., Zehrden, F., Selzer, R. et al. Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson’s Disease. Clin Pharmacokinet 40, 383–393 (2001). https://doi.org/10.2165/00003088-200140050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200140050-00005